drugset / Trial / NCT05497479

Study Evaluating Techniques for Measuring Tear Production

NCT05497479 ↗

Phase 1 Completed 40 enrolled Aerie Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This will be a vehicle-controlled, masked, randomized study conducted at a single site in the United States. All participants enrolled will have Dry Eye Disease (DED). The study will consist of 2 Visits. At Visit 1, eligibility will be assessed at Screening. All eligible subjects will then be enrolled and randomized to one of two treatment groups (1:1): active (0.003% AR-15512) or control (AR-15512 vehicle). Subjects in each treatment group will then be randomized 1:1 to which Visit (Visit 1 or 2) anesthetic will be used with the Schirmer test.

Timeline

Start
2021-12-09
Primary completion
2021-12-10
Completion
2021-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Acoltremon Small molecule 0.003 % Other

Indications